Pulmonx Corporation (LUNG) Q1 2026 Earnings: Narrower-Than-Expected Loss Keeps Sentiment Positive - Earnings Stability Report

Management Commentary

Pulmonx (LUNG) earnings outlook | quarterly results and broader market expectations remain in focus. getLinesFromResByArray error: size == 0 During the first quarter, Pulmonx focused on advancing its commercial strategy for the Zephyr® Endobronchial Valve, the company’s minimally invasive treatment for severe emphysema. While specific revenue amounts were not provided, management highlighted continued progress in procedure volumes and physician training initiatives. The slightly better‑than‑expected EPS outcome suggests disciplined cost control in R&D and SG&A, as the company balances investment in market expansion with operational efficiency. Gross margin trends remain a key area of scrutiny, but without disclosed revenue data, investors must await the full filing for detailed segment performance. The company’s ability to narrow sequential losses could signal improving leverage from its installed base of treatment centers. Pulmonx Corporation (LUNG) Q1 2026 Earnings: Narrower-Than-Expected Loss Keeps Sentiment Positive getLinesFromResByArray error: size == 0getLinesFromResByArray error: size == 0Pulmonx Corporation (LUNG) Q1 2026 Earnings: Narrower-Than-Expected Loss Keeps Sentiment Positive getLinesFromResByArray error: size == 0getLinesFromResByArray error: size == 0

Forward Guidance

Pulmonx (LUNG) earnings outlook | quarterly results and broader market expectations remain in focus. getLinesFromResByArray error: size == 0 Looking ahead, Pulmonx management may provide updated guidance for the remainder of 2026 during the earnings call. The company likely reiterated its focus on expanding reimbursement coverage and driving adoption of the Zephyr valve in both U.S. and international markets. Given the early stage of the product’s penetration, revenue growth could accelerate as more physicians become proficient with the procedure. However, risks remain, including potential delays in hospital buying cycles, competitive pressures from alternative therapies, and macroeconomic headwinds affecting elective procedure volumes. The company anticipates that ongoing clinical data will support favorable payer decisions, which may further support long‑term revenue expansion. Pulmonx Corporation (LUNG) Q1 2026 Earnings: Narrower-Than-Expected Loss Keeps Sentiment Positive getLinesFromResByArray error: size == 0getLinesFromResByArray error: size == 0Pulmonx Corporation (LUNG) Q1 2026 Earnings: Narrower-Than-Expected Loss Keeps Sentiment Positive getLinesFromResByArray error: size == 0getLinesFromResByArray error: size == 0

Market Reaction

Pulmonx (LUNG) earnings outlook | quarterly results and broader market expectations remain in focus. getLinesFromResByArray error: size == 0 Following the earnings release, Pulmonx shares rose 0.65%, indicating a mildly positive market reception to the EPS beat. Analysts may view the in‑line loss as evidence that the company is managing costs effectively while preserving investment in growth. Yet, the absence of revenue disclosure leaves uncertainty regarding top‑line momentum. Key items to watch include future quarterly revenue disclosures, procedure volume trends, and any updates on the company’s path to profitability. With the stock trading near recent lows, sustained execution on commercial expansion could provide a catalyst. Investors should monitor upcoming regulatory and reimbursement decisions that may affect near‑term performance. Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Pulmonx Corporation (LUNG) Q1 2026 Earnings: Narrower-Than-Expected Loss Keeps Sentiment Positive getLinesFromResByArray error: size == 0getLinesFromResByArray error: size == 0Pulmonx Corporation (LUNG) Q1 2026 Earnings: Narrower-Than-Expected Loss Keeps Sentiment Positive getLinesFromResByArray error: size == 0getLinesFromResByArray error: size == 0